ACADMEDIUM SIGNALFINANCIAL10-K

ACAD demonstrated solid revenue growth of 40.4% while experiencing a substantial decline in operating income despite higher net income, suggesting significant non-operating income contributions.

The disconnect between substantially higher net income and lower operating income indicates ACAD benefited from significant non-operating gains that may not be sustainable. The company's core operations show mixed signals with strong revenue growth but compressed operating margins, requiring careful monitoring of underlying business fundamentals.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

ACAD posted strong top-line growth with revenue expanding 40.4% to $726.4M and gross profit growing 35.1%, but operating income fell meaningfully to $104.8M from $230.8M, indicating margin compression or higher operating expenses. Despite weaker operating performance, net income grew substantially to $391.0M, suggesting significant non-operating gains boosted bottom-line results. The balance sheet strengthened notably with stockholders' equity rising 67.5% to $1.2B, though cash declined 44.4% and operating cash flow dropped 30.4%, indicating the company invested heavily or returned capital to shareholders.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+72.7%
$226.5M→$391.0M

Net income grew 72.7% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
+67.5%
$732.8M→$1.2B

Equity base grew 67.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Income
P&L
-54.6%
$230.8M→$104.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-44.4%
$319.6M→$177.7M

Cash declined 44.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Revenue
P&L
+40.4%
$517.2M→$726.4M

Strong top-line growth of 40.4% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
+35.1%
$507.1M→$684.8M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Assets
Balance Sheet
+31.7%
$1.2B→$1.6B

Asset base grew 31.7% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-30.4%
$157.7M→$109.8M

Operating cash flow fell 30.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-29.8%
$394.9M→$277.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-26%
$455.0M→$336.8M

Liabilities reduced 26% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 18, 2026, 170,494,613 shares of the registrant s common stock, $0.0001 par value, were outstanding.
The regulatory approval processes in the EU and outside North America are lengthy, time consuming and inherently unpredictable, and, if we do not obtain regulatory approval of trofinetide outside North America, we will not be able to market trofinetide outside North America, which will limit our trofinetide commercial revenues.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
We have incurred, and expect to continue to incur, significant costs as a result of laws, regulations and standards relating to various aspects of our business, including corporate governance, work force initiatives and other matters, and failure to comply with such laws, regulations and standards could adversely affect our business.
Company Overview We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.
+7 more — sign up free →
REMOVED
As of February 18, 2025, 166,788,517 shares of the registrant s common stock, $0.0001 par value, were outstanding.
If we do not obtain regulatory approval of trofinetide outside North America, we will not be able to market trofinetide outside North America, which will limit our commercial revenues.
We have a history of net losses and we may not be able to predict the extent of future losses.
We have incurred, and expect to continue to incur, significant costs as a result of laws and regulations relating to corporate governance and other matters.
Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →